BUTAZOLIDIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Butazolidin, and when can generic versions of Butazolidin launch?
Butazolidin is a drug marketed by Novartis and is included in one NDA.
The generic ingredient in BUTAZOLIDIN is phenylbutazone. There are nine drug master file entries for this compound. Additional details are available on the phenylbutazone profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for BUTAZOLIDIN?
- What are the global sales for BUTAZOLIDIN?
- What is Average Wholesale Price for BUTAZOLIDIN?
Summary for BUTAZOLIDIN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 118 |
| Patent Applications: | 3,803 |
| DailyMed Link: | BUTAZOLIDIN at DailyMed |
US Patents and Regulatory Information for BUTAZOLIDIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Novartis | BUTAZOLIDIN | phenylbutazone | CAPSULE;ORAL | 008319-009 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Novartis | BUTAZOLIDIN | phenylbutazone | TABLET;ORAL | 008319-008 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
